New pill shows promise against rare bile duct cancer in Late-Stage trial

NCT ID NCT07328919

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tests a new oral drug, TT-00420, against standard chemotherapy for people with advanced bile duct cancer that has a specific genetic change (FGFR2). The trial includes 138 adults whose cancer worsened after initial treatment. The goal is to see if the new drug can slow cancer growth better than chemo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, China

    Contact

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China

  • Eastern Hepatobiliary Surgery Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Hospital

    Shanghai, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.